Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), relating to its proposed sale to Alfasigma S.p.A. Under the terms of the agreement, ICPT shareholders are expected to receive $19.00 in cash per share they own.
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), relating to its proposed sale to Alfasigma S.p.A. Under the terms of the agreement, ICPT shareholders are expected to receive $19.00 in cash per share they own.